But camizestrant’s use could depend on uptake of monitoring – for now.

As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

Any hopes of differentiation could come down to side effects.

BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.

Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.

DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.

In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo.

Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.